The Experts below are selected from a list of 163716 Experts worldwide ranked by ideXlab platform
Kn Sigmon - One of the best experts on this subject based on the ideXlab platform.
-
Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.
American heart journal, 2018Co-Authors: Jennifer B. Green, Lawrence A. Leiter, Salim Janmohamed, Adrian F. Hernandez, Ralph B. D'agostino, Christopher B. Granger, Nigel P. Jones, Drusilla Noronha, Rachael Russell, Kn SigmonAbstract:Abstract Background Albiglutide is a long-acting glucagon-like peptide-1 receptor agonist that improves glycemic control in patients with type 2 diabetes mellitus (T2DM). Harmony Outcomes is a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major adverse cardiovascular (CV) events in patients with T2DM and established CV disease. Methods The trial was designed to recruit 9,400 patients aged ≥40 years with T2DM, prior atherosclerotic CV disease, and suboptimal glycemic control. Participants were assigned in a 1:1 ratio to albiglutide 30 mg (potentially increasing to 50 mg) or matching placebo administered once weekly by subcutaneous injection. The trial will continue until ≥611 confirmed primary outcome events (CV death, myocardial infarction, or stroke) occur over a median follow-up of at least 1.5 years. Results A total of 9,463 patients were enrolled at 611 sites in 28 countries between July 2015 and December 2016. The mean age was 64.1 years; duration of T2DM, 13.8 years; and glycated hemoglobin, 8.7%. The percentage of patients with prior coronary artery disease was 70.5%; peripheral arterial disease, 25.0%; stroke, 17.7%; heart failure, 20.2%; and chronic kidney disease, 22.6%. Conclusions Harmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the glucagon-like peptide-1 receptor agonist class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in Drug Structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Sandra Isabel Simonetti - One of the best experts on this subject based on the ideXlab platform.
-
Surface modification vs sorption strength: Study of nedaplatin Drug supported on silica
Applied Surface Science, 2019Co-Authors: E. Noseda Grau, G. Román, Graciela Petra Brizuela, Alfredo Juan, Sandra Isabel SimonettiAbstract:Abstract The interaction of nedaplatin Drug with modified SiO2 (0 0 1) surfaces has been investigated within the framework of Density Functional Theory. Nedaplatin molecule is adsorbed spontaneously onto silica surfaces. Silica surface prevents Drug degradation allowing the chemical attachment without any impact on the Drug Structure itself. The nedaplatin sorption is mainly governed by H-bonding interactions on hydrated and trimethylsilane-functionalized surfaces, while the Drug is major stabilized by N O, O O interactions and H partial dissociation on dehydrated silica. The differences on the adsorption strength could be used in future studies to control the Drug release, developing delivery silica systems according therapy requirements.
Jennifer B. Green - One of the best experts on this subject based on the ideXlab platform.
-
Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.
American heart journal, 2018Co-Authors: Jennifer B. Green, Lawrence A. Leiter, Salim Janmohamed, Adrian F. Hernandez, Ralph B. D'agostino, Christopher B. Granger, Nigel P. Jones, Drusilla Noronha, Rachael Russell, Kn SigmonAbstract:Abstract Background Albiglutide is a long-acting glucagon-like peptide-1 receptor agonist that improves glycemic control in patients with type 2 diabetes mellitus (T2DM). Harmony Outcomes is a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major adverse cardiovascular (CV) events in patients with T2DM and established CV disease. Methods The trial was designed to recruit 9,400 patients aged ≥40 years with T2DM, prior atherosclerotic CV disease, and suboptimal glycemic control. Participants were assigned in a 1:1 ratio to albiglutide 30 mg (potentially increasing to 50 mg) or matching placebo administered once weekly by subcutaneous injection. The trial will continue until ≥611 confirmed primary outcome events (CV death, myocardial infarction, or stroke) occur over a median follow-up of at least 1.5 years. Results A total of 9,463 patients were enrolled at 611 sites in 28 countries between July 2015 and December 2016. The mean age was 64.1 years; duration of T2DM, 13.8 years; and glycated hemoglobin, 8.7%. The percentage of patients with prior coronary artery disease was 70.5%; peripheral arterial disease, 25.0%; stroke, 17.7%; heart failure, 20.2%; and chronic kidney disease, 22.6%. Conclusions Harmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the glucagon-like peptide-1 receptor agonist class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in Drug Structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Gonzalo Colmenarejo - One of the best experts on this subject based on the ideXlab platform.
-
in silico prediction of Drug binding strengths to human serum albumin
ChemInform, 2003Co-Authors: Gonzalo ColmenarejoAbstract:Drug binding to Human Serum Albumin (HSA) is an area of intense research. The pharmacokinetics and pharmacodynamics of Drugs are strongly affected by their binding to this protein. In this article, the field is reviewed, as well as our models to predict Drug-binding affinities to HSA from Drug Structure. The physiological role of HSA is described, as well as its influence in Drug action. The crystal Structures of this protein are discussed, emphasizing the two Drug-binding sites and the fatty acids binding sites observed therein. The advantages of using high-performance affinity chromatography to rapidly screen Drugs for HSA binding are explained. The different QSAR models for HSA binding of restricted families of Drugs (both from other groups and our group) are enumerated. Finally, a detailed description of our general models to predict Drug-binding strengths to HSA from Structure is given. It is expected for these models to be useful in Drug design and pharmaceutical research.
-
in silico prediction of Drug binding strengths to human serum albumin
Medicinal Research Reviews, 2003Co-Authors: Gonzalo ColmenarejoAbstract:Drug binding to Human Serum Albumin (HSA) is an area of intense research. The pharmacokinetics and pharmacodynamics of Drugs are strongly affected by their binding to this protein. In this article, the field is reviewed, as well as our models to predict Drug-binding affinities to HSA from Drug Structure. The physiological role of HSA is described, as well as its influence in Drug action. The crystal Structures of this protein are discussed, emphasizing the two Drug-binding sites and the fatty acids binding sites observed therein. The advantages of using high-performance affinity chromatography to rapidly screen Drugs for HSA binding are explained. The different QSAR models for HSA binding of restricted families of Drugs (both from other groups and our group) are enumerated. Finally, a detailed description of our general models to predict Drug-binding strengths to HSA from Structure is given. It is expected for these models to be useful in Drug design and pharmaceutical research. © 2003 Wiley Periodicals, Inc. Med Res Rev, 23, No. 3, 275-301, 2003
E. Noseda Grau - One of the best experts on this subject based on the ideXlab platform.
-
Surface modification vs sorption strength: Study of nedaplatin Drug supported on silica
Applied Surface Science, 2019Co-Authors: E. Noseda Grau, G. Román, Graciela Petra Brizuela, Alfredo Juan, Sandra Isabel SimonettiAbstract:Abstract The interaction of nedaplatin Drug with modified SiO2 (0 0 1) surfaces has been investigated within the framework of Density Functional Theory. Nedaplatin molecule is adsorbed spontaneously onto silica surfaces. Silica surface prevents Drug degradation allowing the chemical attachment without any impact on the Drug Structure itself. The nedaplatin sorption is mainly governed by H-bonding interactions on hydrated and trimethylsilane-functionalized surfaces, while the Drug is major stabilized by N O, O O interactions and H partial dissociation on dehydrated silica. The differences on the adsorption strength could be used in future studies to control the Drug release, developing delivery silica systems according therapy requirements.
